3 BJP workers killed as their vehicle hits tree while returning from nomination procession

Mysuru, Mar 13: A state-of-the-art viral research laboratory in the city has been identified as one of the testing laboratories for the detection of COVID-19, official sources said here on Friday.

The samples of suspected cases could be sent to the lab for analysis and it would take about three hours to get the results.

The Viral Research and Diagnostic Laboratory (VRDL), which was set up from Central grants and functions at the Microbiology Department of K.R. Hospital, has been authorised to carry out the tests. This lab in Mysuru is among the 52-plus laboratories in the country.

Though the VRDL is equipped to carry out the tests, the sole authority of confirming the virus lies with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV) in Pune. VRDL is also the sole agency for collection and transportation of suspected samples of COVID-19 to NIV.

VRDL, which is part of the Mysore Medical College and Research Institute, functions on the advice of NIV.

According to the guidelines issued by ICMR, the results of the tests done here have to be shared with NIV the same day and the labs are not supposed to disclose the results since the NIV is the only authority to declare positive cases. Also, confirmation from the NIV should be awaited in case the samples test negative for COVID-19. The ICMR, in the guidelines made available on its website, has advised clinicians at labs to isolate the patient tested positive for COVID-19 in the identified facility and follow bio-safety precautions.

VRDL is a part of a network of labs established by the Department of Health Research, Government of India. The rise in the number of viral outbreaks and the resultant mortality had been cited as key reasons for the launch of network of such hi-tech labs in the country.

The NIV and the National Centre for Disease Control, Delhi, are the top laboratories for the network, while the National Institute of Epidemiology, Chennai, is the supervising authority for the data generated by the network of labs, sources added.

Bengaluru, Jul 22: Karnataka's Covid-19 task force on Tuesday decided that the state government will regulate the supply of Remdesivir, the drug used in the treatment of coronavirus infected patients, to private hospitals to check black marketing and hoarding.

"Remdesivir which is currently available in the government hospitals will be supplied to private hospitals through the government.

This will help curb black marketing of this drug," Medical Education Minister K Sudhakar's office said in a release.

Along with Sudhakar, other task force members, including Health Minister Sriramulu, Deputy Chief Minister C N Ashwath Narayan and Chief Secretary T M Vijay Bhaskar attended the meeting. However, Home Minister Basavaraj Bommai was not part of it as he was out of Bengaluru.

At the meeting, the government has also fixed the rate for Covid-19 tests in private labs- Rs 2,000 for government referred cases and 3,000 for self-reporting cases.

It was also decided to purchase 4 lakh antigen test kits and 5 lakh swab test kits to ramp up testing, the release said, adding that approvals have also been given for additional drugs for the treatment of Covid-19 patients.

The decisions also included increasing monthly salary for Ayush doctors to 48,000, MBBS doctors to 80,000 and nurses to get 30,000 for next 6 months.

The task force also made it clear that private hospitals have to reserve 50 percent beds for the government for Covid-19 treatment. The remaining 50 percent can be used by the private hospitals for Covid-19 and non-Covid-19 treatment.

Private hospitals provide treatment under Ayushman Bharat scheme (ABARK) for Covid-19 patients.

Those cases in which treatment does not cover under the scheme can be charged as per the user charges, the release said.

A committee will be formed to supervise and recommend the purchase of equipment and medicines for Covid-19 treatment, which will be headed by ACS, ITBT Department.

Approval has been given for the procurement of N-95 masks and lakh PPE kits for the safety of healthcare workers. The decision also has been taken to connect oxygen pipeline to 4,736 beds in 17 government medical colleges, which will enable high flow oxygen for these beds besides being beneficial for future use as well.

According to the release, 16 RTPCR and 15 Automated RNA extraction units will be established to ramp up testing and this will help achieve the target of 50,000 tests per day. "On the whole approvals given for purchase of equipment and upgradation of existing facilities at government hospitals is estimated to be about Rs 500 Crore," it added.

Bengaluru, Feb 25: Infosys is all set to announce a cyber defence centre in Indianapolis to complement its technology and innovation centre inaugurated early last year.

This will be Infosys' seventh global cyber defence centre. According to its recent cybersecurity report titled 'Assuring Digital Trust,' 83 per cent of executives view cybersecurity as critical, yet 67 per cent are still struggling to have security embedded.

The cyber defence centre will provide end-to-end, real-time, 24x7 cyber security monitoring and protection services to support and guide American businesses in their digital transformation journey, it said.

The facility is dedicated and organised to prevent, detect, assess and respond to cybersecurity threats and breaches.

Client environment will be monitored round the clock, adopting a follow-the-sun model to deliver services like 24x7 security monitoring, management and remediation, threat hunting, security analytics, incident discovery and response, compliance reporting and malware analysis.

Vishal Salvi, Chief Information Security Officer and Head of Cyber Security Practice at Infosys, said the cyber defence centre is staffed with expert security analysts with niche skills around threat research and intelligence gathering to deliver best-in-class services to customers.

"Additionally, advanced data analytics and machine learning models are deployed to detect zero-day threats by unknown threat actors. This supports our commitment to helping our customers build a resilient cybersecurity programme that operates at scale while increasing operational efficiency and reducing costs," he said in a statement.